文献速递眼底病与葡萄膜炎

估算基础研究的公共与患者节省——光学相干断层扫描指导抗血管内皮生长因子治疗的研究

Estimating Public and Patient Savings From Basic Research-A Study of Optical Coherence Tomography in Managing Antiangiogenic Therapy.
PubMed 文献 · Am J Ophthalmol · 2017-12-07

该观察性队列研究比较了光学相干断层扫描(OCT)指导新生血管性年龄相关性黄斑变性(nvAMD)抗血管内皮生长因子(anti-VEGF)治疗为患者和联邦医疗保险(Medicare)带来的节省与国立卫生研究院(NIH)和国家科学基金会(NSF)对OCT研发的投入。

要点

  • 90亿美元相当于NIH和NSF资助OCT研发投入的21倍回报。
  • 所有成本和节省均按年折现率3%折现并调整为2015年美元。

核心结论

  • 尽管政府资助研究的总体成本效益比难以估算,因收益可能分散且延迟,但20年来对OCT的投入仅通过改善个性化治疗在几年内就已多次收回。

研究设计与样本

  • 观察性队列研究,使用2012至2015年Medicare按服务收费(FFS)受益人的Medicare提供者利用与支付数据,以及2008年100% FFS Part B Medicare索赔文件。
  • 通过检索NIH和NSF从成立至2015年授予的资助来确定OCT研究成本。

主要发现

  • 90亿美元代表通过NIH和NSF资助开发该技术的政府投资回报为21倍。

关键数值与推荐

  • 主要结局指标为Medicare按现行 procedural terminology 代码追踪的玻璃体腔注射(67028)、视网膜OCT成像(92134)和抗VEGF治疗特定J代码(J0178、J2778、J9035、J3490和J3590)的支出。
  • 所有成本和节省均按年折现率3%折现并调整为2015年美元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare patient and Medicare savings from the use of optical coherence tomography (OCT) in guiding therapy for neovascular age-related macular degeneration (nvAMD) to the research investments made in developing OCT by the National Institutes of Health (NIH) and the National Science Foundation (NSF). DESIGN: Observational cohort study. METHODS: Main outcome measures were spending by Medicare as tracked by Current Procedural Terminology codes on intravitreal injections (67028), retinal OCT imaging (92134), and anti-vascular endothelial growth factor (anti-VEGF) treatment-specific J-codes (J0178, J2778, J9035, J3490, and J3590). These claims were identified from the Medicare Provider Utilization and Payment Data from the Centers for Medicare and Medicaid Services among fee-for-service (FFS) Medicare beneficiaries from 2012 to 2015; 2008 claims were acquired from the 100% FFS Part B Medicare Claims File. OCT research costs were determined by searching for grants awarded by NIH and NSF from inception to 2015. All costs and savings were discounted by 3% annually and adjusted for inflation to 2015 dollars. RESULTS: From 2008 to 2015, the United States government and nvAMD patients have accrued an estimated savings of $9.0 billion and $2.2 billion, respectively, from the use of OCT to guide personalized anti-VEGF treatment. The $9.0 billion represents a 21-fold return on government investment into developing the technology through NIH and NSF grants. CONCLUSIONS: Although an overall cost-benefit ratio of government-sponsored research is difficult to estimate because the benefit may be diffuse and delayed, the investment in OCT over 2 decades has been recouped many times over in just a few years through better personalized therapy.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Windsor MA, Sun SJJ, Frick KD, et al. Estimating Public and Patient Savings From Basic Research-A Study of Optical Coherence Tomography in Managing Antiangiogenic Therapy. Am J Ophthalmol. 2017. PMID: 29224686. doi:10.1016/j.ajo.2017.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。